FDA approves Pylarify for diagnosis of advanced/recurrent forms of prostate cancer

In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer. … READ MORE …

FDA approves first gallium-68 PSMA PET scan imaging agent in US, BUT …

Yesterday the US Food and Drug Administration (FDA) gave its approval for the first gallium-68 prostate-specific membrane antigen imaging agent (Ga-67 PSMA-11), for the use in association with positron emission tomography (PET) scanning for the evaluation of men with suspected prostate cancer — and most particularly for those men  with high-risk characteristics suggesting the possibility of metastasis, including men with newly diagnosed or recurrent disease. However, here’s the “but”… READ MORE …

Survey on imaging in the management of prostate cancer

Members of the Coalition for Biomedical Imaging and Bioengineering Research (CIBR) are interested in patient perspectives  and experiences in relation to imaging in the diagnosis, work-up, and management of men with or suspected of having prostate cancer. … READ MORE …

Imaging studies for men with recurrent prostate cancer

We had previously reported on a presentation by Calais et al. earlier this year. … READ MORE …

Early data suggest 18F-DCFPyL PET/CT scans can change patient management

A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …

Next-generation imaging in the management of advanced prostate cancer

A new article in the most recent issue of the Journal of Urology provides recommendations for clinicians as to the appropriate, current use of “next-generation” imaging in the treatment of advanced prostate cancer. … READ MORE …

Progenics reports outcome of OSPREY 2301 trial of PyL™

In a media release issued earlier this morning, Progenics Pharmaceuticals has announced the outcome of a Phase II/III trial of their proprietary, PSMA-targeted imaging agent PyL (also known as 18F-DCFPyL) for identification of prostate cancer. … READ MORE …

Trial of new imaging agent nears completion

Early this morning, Progenics Pharmaceuticals announced completion of enrollment of patients in the Phase II/III OSPREY trial of a new PSMA-targeted PET/CT imaging agent for detection of prostate cancer. … READ MORE …

Two leading women talk about the future of treatment of advanced prostate cancer

Nearly 30 years ago, when your sitemaster first attended a prostate cancer meeting (in 1989) related to the upcoming approval of a new drug called flutamide, he doesn’t remember there being a single clinician at the meeting who was female — out of the 150 or so urologists and medical oncologists who had been invited. … READ MORE …

Copper-64 PET/CT scanning for biochemically relapsing prostate cancer

A group of Italian researchers have apparently shown that a copper-64 dichloride-based radiotracing agent (64CuCl2) is better than currently-used 18FCl radiotracers in the detection of biochemically recurrent prostate cancer with PET/CT scans … READ MORE …

FDA approves the first 7 T MRI device for clinical use in the US

So for those currently dissatisfied with the capabilities of 1.5 T and 3 T MRI imaging technology, the US Food and Drug Administration has just approved a 7 T MRI device called a “Siemens Magnetom Terra”. … READ MORE …

More reports from the EAU “Update on Prostate Cancer”

Dr. Zachary Klaassen and UroToday have provided us with four more interesting summaries of presentations by faculty at the European Association for Urology (EAU)’s meeting in Vienna last weekend. … READ MORE …

What’s luminal water imaging, and do we need to care?

Two recent papers by Sabouri et al. have suggested that a new MRI techique known as “luminal water imaging” may be able to improve the ability of MR scans to identify and grade prostate cancer prior to biopsy. … READ MORE …

Carbon-11-labeled sarcosine as a prostate cancer imaging agent

A new paper in the Journal of Nuclear Medicine has reported the first use of [11C]sarcosine in combination with PET/CT scanning as a technique for imaging prostate cancer in man. … READ MORE …

New CureTalks program on modern forms of prostate imaging

Our next CureTalks program will be on the evolving role of imaging in the diagnosis and management of prostate cancer on Thursday, July 27, at 5:00 p.m. Pacific / 8:00 p.m. Eastern time. … READ MORE …